文章：

BRAF抑制剂在转移性结直肠癌中的应用及耐药机制：文献综述

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature

原文发布日期：31 October 2023

DOI: 10.3390/cancers15215243

类型: Article

开放获取: 是

英文摘要：

Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.

摘要翻译： 

携带BRAF突变的转移性结直肠癌（mCRC）具有独特的生物学和分子特征，使其区别于其他结直肠癌亚型。目前这类肿瘤的标准治疗方案是化疗（CT）联合血管内皮生长因子抑制剂。近年来，针对BRAF的靶向治疗以及针对微卫星不稳定性（MSI）病例的免疫治疗（IT）已融入临床实践。尽管靶向治疗已显示出良好疗效，但相当一部分应答患者最终会产生治疗耐药性。本文旨在综述现有文献中关于BRAF抑制剂耐药机制及其潜在应对策略的研究进展。

原文链接：

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature